Generex Biotechnology Corporation Announces Particulars of Conference Call with Members of the Antigen Express Scientific Advisory Board
Published: Jul 12, 2013
WORCESTER, Mass. and TORONTO, July 12, 2013 /PRNewswire/ -- Generex Biotechnology Corporation (www.generex.com) (OTCBB: GNBT) today announced particulars of the conference call it will be hosting featuring members of the Antigen Express, Inc. (www.antigenexpress.com) Scientific Advisory Board.
The conference call will take place on Wednesday, August 14, 2013 at 10 a.m. EDT. Call-in particulars will be announced prior to the call.
The following members of the Antigen Express Scientific Advisory Board will be the panelists on the call:
- Dr. Gary H. Lyman, MD, MPH, FACP, FRCP (Edin), FASCO is a Professor of Medicine at Duke University School of Medicine, Director of the Comparative Effectiveness and Outcomes Research Program, a Senior Fellow at the Duke Center for Clinical Health Policy Research, and a member of the Duke Cancer Institute and Duke Center for Personalized Medicine. An ASCO member since 1977, Dr. Lyman is a member of the ASCO Board of Directors and Chair-Elect of the Clinical Practice Guidelines Committee and serves on the Editorial Board of the Journal of Clinical Oncology.
- Dr. Gabriel N. Hortobagyi, MD, FACP chairs the department of Breast Medical Oncology and directs the Breast Cancer Research Program at the University of Texas M.D. Anderson Cancer Center, where he also serves as Professor of Medicine and holds the Nellie B. Connally Chair in Breast Cancer.
- Dr. Ian Krop, MD, PhD is an Assistant Professor of Medicine and Director of Clinical Research for the Breast Oncology Center at the Dana-Farber Cancer Institute, Harvard Medical School.
- Dr. Keith L. Knutson, PhD is Oncology Program Director at the Vaccine & Gene Therapy Institute of Florida (VGTI Florida®). His work is focused on immunotherapeutic approaches in breast and ovarian cancers and how vaccines can boost immunity and help the body's defense system fight off these cancers.
- Dr. James J. Mule, PhD is the Executive Vice President and Associate Center Director for Translational Research, the Michael McGillicuddy Endowed Chair for Melanoma Research and Treatment, and the Co-Director of the Donald A. Adam Comprehensive Melanoma Center at the Moffitt Cancer Center.
- Dr. Hope S. Rugo, MD is a Professor of Medicine in the Division of Hematology and Oncology at theUniversity of California San Francisco (UCSF), where she directs Breast Oncology and Clinical Trials Education. Dr. Rugo is a member of the breast core committee of the Alliance for Clinical Trials in Oncology Network, where she is the principal investigator of CALGB 40502, a fully accrued phase III trial comparing novel chemotherapy agents in the treatment of advanced breast cancer. She is also an investigator in the Bay Area Spore at UCSF's Carol Franc Buck Breast Cancer Center and the breast section editor for Cancer.Net, a patient focused publication of ASCO.
- Dr. Samuel Jacobs, MD is an emeritus Clinical Professor in the Department of Medicine, University of Pittsburgh School of Medicine, and the Director of Medical Affairs for the National Surgical Adjuvant Breast and Bowel Project (NSABP).
Dr. Elizabeth Mittendorf, MD, PhD, Assistant Professor, Department of Surgical Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center and the Principal Investigator on the Antigen Express AE37 breast cancer vaccine Phase II trial, will also participate on the panel.
The call will canvass the following topics:
- highlights from the June 2013 Annual Meeting of the American Society of Clinical Oncology (ASCO);
- an update on the on-going Phase II clinical trial of the AE37 breast cancer vaccine;
- the current state of the treatment of breast cancer and treatment trends;
- treatment options for patients who express low levels of HER2;
- a review of antibodies and vaccines in immunotherapy and the importance of CD4+ T cell activation by Ii-Key;
- biomarkers and personalized medicine in cancer care and opportunities for the Ii-Key platform;
- treatment options for triple-negative breast cancer; and
- an update from the National Surgical Adjuvant Breast and Bowel Project (NSABP) and the potential for AE37.
About Generex Biotechnology Corporation
Generex is engaged in the research, development, and commercialization of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist device. Antigen Express, Inc. is a wholly owned subsidiary of Generex. The core platform technologies of Antigen Express comprise immunotherapeutic vaccines for the treatment of malignant, infectious, allergic, and autoimmune diseases. Antigen Express has pioneered the use of specific CD4+ T-helper stimulation technologies in immunotherapy. One focuses on modification of peptides with Ii-Key to increase potency, while a second relies on inhibition of expression of the Ii protein. Antigen Express scientists, and others, have shown clearly that suppression of expression of the Ii protein in cancer cells allows for potent stimulation of T-helper cells and prevents the further growth of cancer cells. For more information, visit the Generex website at www.generex.com or the Antigen Express website at www.antigenexpress.com.
Cautionary Note Regarding Forward-Looking Statements
This release and oral statements made from time to time by Generex representatives in respect of the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plan," "believes," "will," "achieve," "anticipate," "would," "should," "subject to" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase of clinical trials. Because of this, statements regarding the expected timing of clinical trials or ultimate regulatory approval cannot be regarded as actual predictions of when Generex will obtain regulatory approval for any "phase" of clinical trials or when it will obtain ultimate regulatory approval by a particular regulatory agency. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.
SOURCE Generex Biotechnology Corporation
Help employers find you! Check out all the jobs and post your resume.